ライフサイエンスコーパス: histocompatibility antigen

1 acid early transcript (Rae1) and H-60 minor histocompatibility antigen.

2 this issue employed the redesign of a minor histocompatibility antigen.

3 irteen-residue, maternally transmitted minor histocompatibility antigen.

4 ens, although they remained tolerant to host histocompatibility antigens.

5 -specific differentiation antigens and minor histocompatibility antigens.

6 ic antigen-presenting cells presenting minor histocompatibility antigens.

7 the development of humoral immunity to minor histocompatibility antigens.

8 d by donor T cells that recognize host minor histocompatibility antigens.

9 r major histocompatibility antigens or minor histocompatibility antigens.

10 n mismatching for cellular peptides known as histocompatibility antigens.

11 affected tissues and giving rise to multiple histocompatibility antigens.

12 ammation and up-regulation of class I and II histocompatibility antigens.

13 iated with sensitization to mismatched donor histocompatibility antigens.

14 ts that confront the host with foreign minor histocompatibility antigens.

15 is controlled by genetic factors, especially histocompatibility antigens.

16 oligoclonal, pointing to a response to minor histocompatibility antigens.

17 The hypothesis that ICAM-1 acts as a minor histocompatibility antigen and that anti-ICAM-1 antibodi

18 ells in the glands; 4) upregulation of major histocompatibility antigens and adhesive molecules by ep

19 regulate surface expression of class I major histocompatibility antigens and also inhibit tumor necro

20 that recognize mismatched major and/or minor histocompatibility antigens and cause severe damage to h

21 o operational tolerance to the donor's major histocompatibility antigens and long-term acceptance to

22 on of Tregs against major and possibly minor histocompatibility antigens and predict the feasibility

23 and subsequent reduced presentation of minor histocompatibility antigens and reduced ligation of acti

24 nt is acquired tolerance of allogeneic minor histocompatibility antigens and that posttransplant immu

25 rolling the production of antibodies against histocompatibility antigens are of prime importance in o

26 Immune responses to minor histocompatibility antigens are poorly understood and pr

27 ong MHC matched mouse strains, a few unknown histocompatibility antigens are targeted by the cytotoxi

28 the ubiquitous light chain of class I major histocompatibility antigens, as the amyloid fibril prote

29 d the shared antigens do not represent minor histocompatibility antigens, as their sequences are iden

30 ry pathway which reduces expression of major histocompatibility antigens at the plasma membrane and s

31 CD4+ T cell-mediated GVHD across this minor histocompatibility antigen barrier depends on the expres

32 ls (HSCs) when transplanted across the major histocompatibility antigen barriers if transplanted alon

33 ize bone marrow grafts bearing hematopoietic histocompatibility antigens bear surface markers of natu

34 Mismatched histocompatibility antigens between donor organ and host

35 ed specific tolerance to both host and donor histocompatibility antigens, but normal anti-third party

36 -deficient CD8(+) T-cell response to a minor histocompatibility antigen by phenotypic and in vivo ima

37 RFX5 cause bare lymphocyte syndrome or major histocompatibility antigen class II deficiency.

38 The major histocompatibility antigen class II-associated invariant

39 Expression of major histocompatibility antigens class-2 (MHC-II) under non-i

40 genes that are not associated with the major histocompatibility antigen complex genes.

41 ficient B6.gld mice as recipients in a Major Histocompatibility Antigen Complex-matched minor Histoco

42 Minor histocompatibility antigens contribute to the control of

43 Here we describe a human minor histocompatibility antigen created by a polymorphism in

44 On the other hand, the importance of minor histocompatibility antigens derived from nonhematopoieti

45 s alloimmune syndrome in recipients of minor histocompatibility antigen disparate donor cells, showin

46 When transplanted into minor histocompatibility antigen-disparate allogeneic recipien

47 radiation chimeras across the multiple minor histocompatibility antigen-disparate, C57BL/6-->BALB.B c

48 es across a two-haplotype class I plus minor histocompatibility antigen disparity by a 12-d course of

49 ed across a two-haplotype class I plus minor histocompatibility antigen disparity by a 12-day course

50 GVHD and other BMT complications other than histocompatibility antigen disparity.

51 cells that are specific for recipient minor histocompatibility antigens encoded by Y-chromosome gene

52 Allogeneic antibodies against minor histocompatibility antigens encoded on the Y chromosome

53 nor human leukocyte antigen molecules, minor histocompatibility antigens, endothelial cells, RBCs, or

54 epends on an orchestrated immune response to histocompatibility antigens expressed by the grafted tis

55 CAID, but soluble and cell-associated (minor histocompatibility) antigens generated cell-associated A

56 c acid early inducible (RAE-1) and H60 minor histocompatibility antigen genes on mouse chromosome 10

57 c T cell clones specific for the human minor histocompatibility antigen H-Y and restricted by HLA-A*0

58 Antibody response to Y-chromosome encoded histocompatibility antigens (H-Y antigens) was also asso

59 ted that recipient mismatching for the minor histocompatibility antigen HA-1 is associated with acute

60 For minor histocompatibility antigens HA-1 and HA-2, normal cell e

61 BALB.B spleen cells, despite multiple minor histocompatibility antigen (HA) differences.

62 Indirect presentation of minor histocompatibility antigens (HA) as revealed by cross-pr

63 f alloantibody responses against foreign HLA histocompatibility antigens has never been delineated.

64 rkers (intercellular adhesion molecule-1 and histocompatibility antigen HLA-DR) in arteries and arter

65 ition mediated by Ly-49A in the mouse, human histocompatibility antigen (HLA)-B*2705-specific NK clon

66 to late phase trials and to evaluate closely histocompatibility antigen (HLA)-matched banked antigen-

67 ted with the expression of the class I major histocompatibility antigen, HLA-B27.

68 produces HvG against the male specific minor histocompatibility antigen HY.

69 the "missing self" and not the "hemopoietic histocompatibility antigen" hypothesis for HR.

70 morphic genes are known to encode functional histocompatibility antigens in mismatched individuals, b

71 HLA-B27-restricted CTL response to HY minor histocompatibility antigens in rats and mice transgenic

72 eactive CD4+ lymphocytes responding to major histocompatibility antigens in vivo.

73 ncluding recognition of sex-determined minor histocompatibility antigens, influence of sex hormones o

74 ed by the indirect recognition of allogeneic histocompatibility antigens late in transplantation may

75 CD1 family of evolutionarily conserved major histocompatibility antigen-like molecules, controls the

76 In a single minor histocompatibility antigen (male to female)-dependent ao

77 In addition, a better understanding of minor histocompatibility antigens may lead to more targeted im

78 products induced BMT rejection across minor histocompatibility antigen (mHA) barriers.

79 he immune response to DBY, a model H-Y minor histocompatibility antigen (mHA) in a male patient with

80 grafts supplemented with T cells in a minor histocompatibility antigen (mHA)-mismatched mouse model.

81 in susceptibility to immune pressure, minor histocompatibility antigen (mHa)-specific T-cell lines o

82 Human minor histocompatibility antigens (mHA) and clinically relevan

83 Next, we immunized the donor to the minor histocompatibility antigens (mHA) of the recipient by me

84 Minor histocompatibility antigen (mHag) discordances have been

85 toma in a murine model of MHC-matched, minor histocompatibility antigen (mHAg)-mismatched bone marrow

86 Minor histocompatibility antigens (mHAg's) are peptides encode

87 Minor histocompatibility antigens (mHags) are immunogenic pept

88 D because of the presence of recipient minor histocompatibility antigens (mHAgs) in whole-cell tumor

89 donor T cells that recognize recipient minor histocompatibility antigens (mHAgs) is a potential strat

90 ming of donor T cells against putative minor histocompatibility antigens (mHAgs) on the tumor vaccine

91 Minor histocompatibility antigens (mHAgs) present a significan

92 T cell recognition of minor histocompatibility antigens (mHags) underlies allogeneic

93 d major histocompatibility complex and minor histocompatibility antigens (mHAgs).

94 imarily by donor T-cell recognition of minor histocompatibility antigens (mHAgs).

95 Minor histocompatibility antigens (mHAs) are known targets of

96 lloreactive donor T cells against host minor histocompatibility antigens (mHAs) cause graft-versus-ho

97 increased rejection is likely against minor histocompatibility antigens (mHAs).

98 rom donors vaccinated against a single minor histocompatibility antigen (miHA) expressed by leukemia

99 B6 (H-2(b)) recipients primed to donor minor histocompatibility antigen (MiHA) prior to BM transplant

100 Minor histocompatibility antigen (miHA) vaccines have the pote

101 ed, CD4-driven murine GVHD model and a minor histocompatibility antigen (MiHA)-mismatched, CD8-driven

102 lloreactive T cell responses targeting minor histocompatibility antigens (MiHA) expressed on malignan

103 nd the interaction of these cells with minor histocompatibility antigen- (miHA-) mismatched CD8+ T ce

104 D8+ stem cell memory T cells targeting minor histocompatibility antigens (MiHAs) expressed by recipie

105 itude and diversity of CD8 T cells for minor histocompatibility antigens (MiHAs) in patients with sel

106 tiate GVHD by directly presenting host minor histocompatibility antigens (miHAs) to donor CD8 cells.

107 nd recipient were incompatible at many minor histocompatibility antigens (minor H Ags), the CD8 T-cel

108 Minor histocompatibility antigens (minor H antigens) are targe

109 dent GVHD in a mouse model across only minor histocompatibility antigens (minor H antigens).

110 the role of donor Stat1 in MHC-matched minor histocompatibility antigen-mismatched (mHA-mismatched) a

111 the mechanisms of DLI in MHC-matched, minor histocompatibility antigen-mismatched allogeneic chimera

112 compatibility complex-matched multiple minor histocompatibility antigen-mismatched alloHCT using bone

113 may not apply to MHC-matched, multiple minor histocompatibility antigen-mismatched alloSCT, the most

114 In both a minor histocompatibility antigen-mismatched as well as a MHC-h

115 Recipients were H-2-matched, minor histocompatibility antigen-mismatched C57BL/6 mice with

116 ngle Y chromosome-encoded, or multiple minor histocompatibility antigen-mismatched hematopoietic cell

117 ocompatibility Antigen Complex-matched minor Histocompatibility Antigen-mismatched murine model for G

118 ets, and we report that transfusion of minor histocompatibility antigen-mismatched platelets induced

119 n important role in clinical GVHD in a minor histocompatibility antigen-mismatched setting.

120 histocompatibility complex-matched and minor histocompatibility antigen-mismatched unrelated donors a

121 usions (DLIs) were incorporated into a minor histocompatibility antigen-mismatched, T cell-depleted,

122 histocompatibility complex (MHC) and non-MHC-histocompatibility antigen (non-MHC-HA) barriers.

123 The induction of tolerance to the histocompatibility antigens of the organ donor in the lo

124 ntation, donors' T cells can recognize minor histocompatibility antigens on recipient cells and gener

125 o be mediated by T-cell recognition of minor histocompatibility antigens on recipient cells.

126 The only known polymorphic histocompatibility antigens on the fetal trophoblast are

127 by increased recipient mismatching for major histocompatibility antigens or minor histocompatibility

128 The inclusion of SNPs that encode minor histocompatibility antigens or other genetic polymorphis

129 cagon receptor, a ras-related protein (Rad), histocompatibility antigens, PC-1, and fatty acid bindin

130 Minor histocompatibility antigens play a significant role in a

131 (TCR) to peptide antigen presented by major histocompatibility antigens (pMHC) on antigen-presenting

132 when recipient lymphocytes encounter foreign histocompatibility antigens presented by the graft's end

133 ymes to cleavage sites and of class II major histocompatibility antigen-presenting proteins to helper

134 s that humoral and cellular sensitization to histocompatibility antigens prior to and after islet tra

135 poorly defined minor (i.e., other than HLA) histocompatibility antigens remains a serious problem in

136 The GVL effect is directed against minor histocompatibility antigens shared by normal and leukemi

137 tly suppressed the clonal expansion of minor histocompatibility antigen-specific CD8 T cells during t

138 cells do not inhibit allogeneic MHC or minor histocompatibility antigen-specific CTL production), dep

139 arrow is not matched in the clinic for minor histocompatibility antigens, such as those carried by pl

140 murine model that uses differences in minor histocompatibility antigens to generate Scl GVHD.

141 , skin differing from the host only by minor histocompatibility antigens undergoes slower (i.e., chro

142 d donor MHC class I and II, and of H-Y minor histocompatibility antigen was assessed by quantifying p

143 d bone marrow, mismatched for multiple minor histocompatibility antigens, was induced in Fas mutant a

144 with a response to immunodominant host minor histocompatibility antigens, we detected oligoclonal liv

145 sparities in cytoplasmically inherited minor histocompatibility antigens, we examined one hypervariab

146 ng genetic disparity in both major and minor histocompatibility antigens were used for transplantatio

147 Thus, the male-specific H-Y histocompatibility antigen, which is ubiquitously expres

148 ion of these hematopoietically derived minor histocompatibility antigens will induce significant graf

149 Minor histocompatibility antigens with expression restricted t